For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.
Price · 1Y
$169.26
Thesis
AstraZeneca is a diversified large-cap pharma with one of the deepest oncology pipelines in the industry — Tagrisso in lung cancer, the Enhertu antibody-drug conjugate partnered with Daiichi Sankyo, and Imfinzi in immuno-oncology — alongside a major cardio-renal-metabolic franchise led by Farxiga. That breadth across oncology, CRM, respiratory, and rare disease (Alexion) gives unusually durable, broad-based growth.
The metabolic franchise and an emerging obesity / oral-GLP-1 program add a forward leg to a company already compounding. As a high-quality, well-positioned name, the key swings are pipeline-trial outcomes, the pace of its stated revenue-growth ambition, and exposure to China and drug-pricing policy.
Catalysts
- Oncology pipeline readouts (Enhertu, Tagrisso, Imfinzi)
- Cardio-renal-metabolic and obesity program progress
- Revenue-growth ambition execution
- China demand and pricing-policy developments
Recent events
Material filings, federal awards, and regulatory activity. Impact is scored against market cap.
- Jul 23RegulatorySEC
6-K reports EU approval of Ectamah for ER+ breast cancer
- Jul 14DealSEC
AstraZeneca licenses novel EGFR inhibitor (6-K filing).
- Jul 9Trial readoutSEC
6-K filing: update on Cardio-TTransform Phase III trial.
- Jun 29RegulatorySEC
EU approval of Enhertu for HER2+ solid tumors
- Jun 29RegulatorySEC
DATROWAY recommended for approval in EU for TNBC
- Jun 15RegulatorySEC
Truqap approved in the US for prostate cancer per 6-K filing.
- Jun 2Trial initiationClinicalTrials.gov
AstraZeneca Phase 3 trial NCT07430306 (subcutaneous anifrolumab in immunosuppressant- and biologic-naïve SLE) status updated to RECRUITING
- May 29RegulatorySEC
Imfinzi approved in US for early bladder cancer